-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yimaitong is authorized to publish, please do not reprint without permission
.
Thyroid cancer is the most common endocrine malignant tumor, as well as the most common malignant tumor of the head and neck
.
In recent years, the global incidence of thyroid cancer has been increasing year by year, and it has become one of the tumors that have attracted much attention
.
Yimaitong invited Professor Xia Yu from the Department of Ultrasound Medicine of Peking Union Medical College Hospital to share with us the important value and significance of ultrasound in the evaluation of the efficacy of thyroid cancer
.
Professor Xia Yu's personal profile: Chief physician, doctoral supervisor, deputy director of the Department of Ultrasound Medicine, Peking Union Medical College Hospital, and leader of the subspecialized group of thyroid ultrasound
.
He has won the China Scholarship Council Scholarship and the Japan Ultrasound Medical Association Scholarship for long-term study in the United States and Japan
.
From 2018 to 2019, he participated in the organization of medical personnel from the Central Organization Department to assist Tibet
.
Published more than 30 SCI articles, more than 40 Chinese core journal articles, participated in the compilation of 16 professional books, served as deputy editor in 2 13th Five-Year Plan textbooks, and participated in the compilation of 2 domestic guides
.
The guidelines emphasize the importance of ultrasound as a tool for the evaluation of local lesions after treatment.
Professor Xia Yu compared with the "Chinese Society of Clinical Oncology Guidelines for the Diagnosis and Treatment of Persistent/Relapsed and Metastatic Differentiated Thyroid Cancer (2019 Edition)", "Chinese Society of Clinical Oncology Differentiated Thyroid Cancer" The Guidelines for Diagnosis and Treatment (2021 Edition) (hereinafter referred to as the “Guidelines”) have added relevant content on the evaluation of the efficacy of thyroid cancer, clearly pointing out that patients with differentiated thyroid cancer undergo surgical treatment, various local or systemic treatments, and the treatment of local lesions and/or For distant metastatic lesions, their efficacy should be evaluated to guide the formulation of further diagnosis and treatment or follow-up strategies
.
The "Guide" emphasizes the importance of ultrasound examination as an evaluation tool for locally resectable lesions after treatment, and elaborates on the timing of its evaluation, the purpose of the evaluation, and the content of the evaluation
.
There are various clinical treatment methods for thyroid cancer, including surgical treatment, 131I treatment, endocrine therapy, system therapy, ablation therapy, external beam radiation therapy, etc.
, involving ultrasound medicine, pathology, surgery, nuclear medicine, endocrinology, oncology, radiotherapy, etc.
Many disciplines such as science, interventional medicine and laboratory medicine have distinct characteristics of multidisciplinary diagnosis and treatment
.
The "Guide" emphasizes that the efficacy evaluation of thyroid cancer should also be combined with the results of serology and various imaging studies for dynamic efficacy evaluation.
It involves multiple imaging techniques such as ultrasound, CT, MRI, and 131I scanning.
Ultrasound is a local area after multiple treatments.
The first choice for the evaluation of the curative effect of resectable lesions, ultrasound can be used as a surgical resection range to achieve the expected goal; whether the 131I treatment is successful; local lesion changes after ablation, endocrine therapy, external radiation therapy, and targeted therapy; local invasion and remote Evaluation methods for the treatment effect of metastatic lesions
.
The guidelines specify the content of ultrasound evaluation after treatment.
Professor Xia Yu’s “Guidelines” point out that patients after total thyroidectomy, partial resection, and recurrence/metastasis resection should undergo cervical ultrasound to evaluate the thyroid bed and cervical lymph nodes, and cervical ultrasound evaluation after thyroidectomy The contents include thyroid bed, cervical lymph nodes, subcutaneous tissue or/and muscles, internal jugular vein
.
Special attention should be paid to the identification of recurrent neck lesions and benign lesions such as fibro-fatty connective tissue and scar tissue in the thyroid bed after surgery
.
After 131I treatment, an ultrasound examination of the neck should be performed to observe the persistence of the lesion and whether there is a new neck metastasis
.
Patients undergoing cervical external beam radiation therapy undergo cervical ultrasonography to assess whether the local lesions have progressed or not
.
Ultrasound evaluation should be performed immediately after thermal/chemical ablation treatment.
Color Doppler and contrast-enhanced ultrasound can be used to assess the ablation range; the neck ultrasound examination after treatment can observe changes in the size of the lesion and observe whether there are new tumors and lymph node metastases
.
After 125I seed therapy implantation treatment, neck ultrasound examination should be performed regularly to assist in the judgment of curative effect
.
References: [1]Li M, Dal Maso L, Vaccarella S.
Global trends in thyroid cancer incidence and the impact of overdiagnosis.
Lancet Diabetes Endocrinol.
2020;8(6):468-470.
[2]Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin.
2021;71(3):209- 249.
[3] Chinese Society of Clinical Oncology Guidelines Working Committee Thyroid Cancer Expert Committee.
Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Persistent/Relapsed and Metastatic Differentiated Thyroid Cancer-2019.
Cancer Prevention and Treatment, 2019, 32(12) :1051-1079.
.
Thyroid cancer is the most common endocrine malignant tumor, as well as the most common malignant tumor of the head and neck
.
In recent years, the global incidence of thyroid cancer has been increasing year by year, and it has become one of the tumors that have attracted much attention
.
Yimaitong invited Professor Xia Yu from the Department of Ultrasound Medicine of Peking Union Medical College Hospital to share with us the important value and significance of ultrasound in the evaluation of the efficacy of thyroid cancer
.
Professor Xia Yu's personal profile: Chief physician, doctoral supervisor, deputy director of the Department of Ultrasound Medicine, Peking Union Medical College Hospital, and leader of the subspecialized group of thyroid ultrasound
.
He has won the China Scholarship Council Scholarship and the Japan Ultrasound Medical Association Scholarship for long-term study in the United States and Japan
.
From 2018 to 2019, he participated in the organization of medical personnel from the Central Organization Department to assist Tibet
.
Published more than 30 SCI articles, more than 40 Chinese core journal articles, participated in the compilation of 16 professional books, served as deputy editor in 2 13th Five-Year Plan textbooks, and participated in the compilation of 2 domestic guides
.
The guidelines emphasize the importance of ultrasound as a tool for the evaluation of local lesions after treatment.
Professor Xia Yu compared with the "Chinese Society of Clinical Oncology Guidelines for the Diagnosis and Treatment of Persistent/Relapsed and Metastatic Differentiated Thyroid Cancer (2019 Edition)", "Chinese Society of Clinical Oncology Differentiated Thyroid Cancer" The Guidelines for Diagnosis and Treatment (2021 Edition) (hereinafter referred to as the “Guidelines”) have added relevant content on the evaluation of the efficacy of thyroid cancer, clearly pointing out that patients with differentiated thyroid cancer undergo surgical treatment, various local or systemic treatments, and the treatment of local lesions and/or For distant metastatic lesions, their efficacy should be evaluated to guide the formulation of further diagnosis and treatment or follow-up strategies
.
The "Guide" emphasizes the importance of ultrasound examination as an evaluation tool for locally resectable lesions after treatment, and elaborates on the timing of its evaluation, the purpose of the evaluation, and the content of the evaluation
.
There are various clinical treatment methods for thyroid cancer, including surgical treatment, 131I treatment, endocrine therapy, system therapy, ablation therapy, external beam radiation therapy, etc.
, involving ultrasound medicine, pathology, surgery, nuclear medicine, endocrinology, oncology, radiotherapy, etc.
Many disciplines such as science, interventional medicine and laboratory medicine have distinct characteristics of multidisciplinary diagnosis and treatment
.
The "Guide" emphasizes that the efficacy evaluation of thyroid cancer should also be combined with the results of serology and various imaging studies for dynamic efficacy evaluation.
It involves multiple imaging techniques such as ultrasound, CT, MRI, and 131I scanning.
Ultrasound is a local area after multiple treatments.
The first choice for the evaluation of the curative effect of resectable lesions, ultrasound can be used as a surgical resection range to achieve the expected goal; whether the 131I treatment is successful; local lesion changes after ablation, endocrine therapy, external radiation therapy, and targeted therapy; local invasion and remote Evaluation methods for the treatment effect of metastatic lesions
.
The guidelines specify the content of ultrasound evaluation after treatment.
Professor Xia Yu’s “Guidelines” point out that patients after total thyroidectomy, partial resection, and recurrence/metastasis resection should undergo cervical ultrasound to evaluate the thyroid bed and cervical lymph nodes, and cervical ultrasound evaluation after thyroidectomy The contents include thyroid bed, cervical lymph nodes, subcutaneous tissue or/and muscles, internal jugular vein
.
Special attention should be paid to the identification of recurrent neck lesions and benign lesions such as fibro-fatty connective tissue and scar tissue in the thyroid bed after surgery
.
After 131I treatment, an ultrasound examination of the neck should be performed to observe the persistence of the lesion and whether there is a new neck metastasis
.
Patients undergoing cervical external beam radiation therapy undergo cervical ultrasonography to assess whether the local lesions have progressed or not
.
Ultrasound evaluation should be performed immediately after thermal/chemical ablation treatment.
Color Doppler and contrast-enhanced ultrasound can be used to assess the ablation range; the neck ultrasound examination after treatment can observe changes in the size of the lesion and observe whether there are new tumors and lymph node metastases
.
After 125I seed therapy implantation treatment, neck ultrasound examination should be performed regularly to assist in the judgment of curative effect
.
References: [1]Li M, Dal Maso L, Vaccarella S.
Global trends in thyroid cancer incidence and the impact of overdiagnosis.
Lancet Diabetes Endocrinol.
2020;8(6):468-470.
[2]Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin.
2021;71(3):209- 249.
[3] Chinese Society of Clinical Oncology Guidelines Working Committee Thyroid Cancer Expert Committee.
Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Persistent/Relapsed and Metastatic Differentiated Thyroid Cancer-2019.
Cancer Prevention and Treatment, 2019, 32(12) :1051-1079.
